Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-240 vs Optive in Healthy Volunteers
NCT06375343Phase 1Not yet recruiting
- Sponsor
- Laboratorios Sophia
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 1, randomised trial of PRO-240 in dry eye disease (DED) (2 arms), sponsored by Laboratorios Sophia. Primary endpoint: Incidence of unexpected adverse events related to the interventions at Day 11. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
PRO-240
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06375343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375343.